Drug General Information
Drug ID	D0F5BL
Former ID	DIB015756
Drug Name	EXO-230
Synonyms	GLY-230
Indication	Diabetic neuropathy [ICD9: 250, 250.6, 356.0, 356.8; ICD10:E11.40]		Phase 1/2	[522142]
Company	Glycadia Inc
Structure		Download 2D MOL 3D MOL
Canonical SMILES	N(c1c(CC(=O)O)cccc1)c1cc(Cl)ccc1
Target and Pathway
Target(s)	Prostaglandin G/H synthase 1	Target Info	Agonist	[544348]
BioCyc Pathway	C20 prostanoid biosynthesis
KEGG Pathway	Arachidonic acid metabolism
	Metabolic pathways
	Platelet activation
	Serotonergic synapse
NetPath Pathway	TGF_beta_Receptor Signaling Pathway
PANTHER Pathway	Inflammation mediated by chemokine and cytokine signaling pathway
PathWhiz Pathway	Arachidonic Acid Metabolism
WikiPathways	Prostaglandin Synthesis and Regulation
	Arachidonic acid metabolism
	Phase 1 - Functionalization of compounds
	Eicosanoid Synthesis
	Selenium Micronutrient Network
References
Ref 522142	ClinicalTrials.gov (NCT00544934) Multiple Dose Trial of Anti-glycation Agent GLY-230 in Healthy and Diabetic Subjects. U.S. National Institutes of Health.
Ref 544348	Inhibiting Amadori-modified albumin formation improves biomarkers of podocyte damage in diabetic rats. Physiol Rep. 2013 September; 1(4): e00083.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.